Sarepta Therapeutics, Inc. announced Arthur "Art" Krieg, M.D., has been named senior vice president and chief scientific officer. In this role, Dr. Krieg will lead the company's drug discovery and early-stage research activities. Dr. Krieg joins Sarepta from RaNA Therapeutics, where he served as chief executive officer since he co-founded the company in 2011.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
156.8 USD | -0.79% | -4.33% | +62.55% |
26/06 | Monetary policy is getting even more confusing | |
26/06 | Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.55% | 1.49TCr | |
+15.82% | 12TCr | |
+20.35% | 11TCr | |
+17.47% | 2.6TCr | |
-25.31% | 1.94TCr | |
-19.51% | 1.59TCr | |
-19.67% | 1.51TCr | |
-46.87% | 1.51TCr | |
+6.34% | 1.39TCr | |
+114.07% | 1.08TCr |
- Stock Market
- Equities
- SRPT Stock
- News Sarepta Therapeutics, Inc.
- Sarepta Therapeutics Names Arthur Krieg, M.D., as Senior Vice President and Chief Scientific Officer